AC Immune First Half 2026 Financial and Corporate Update AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, provided a corporate and financial update for the half-year ended June 30, 2026. The period saw strong advances across the Company’s pipeline, with its partnered programs generating considerable milestone payments as […]